Cyclo Therapeutics Inc banner

Cyclo Therapeutics Inc
NASDAQ:CYTH

Watchlist Manager
Cyclo Therapeutics Inc Logo
Cyclo Therapeutics Inc
NASDAQ:CYTH
Watchlist
Price: 99 USD 12.08% Market Closed
Market Cap: $20.7m

Cyclo Therapeutics Inc
Inventory

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Cyclo Therapeutics Inc
Inventory Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Inventory CAGR 3Y CAGR 5Y CAGR 10Y
Cyclo Therapeutics Inc
NASDAQ:CYTH
Inventory
$236.1k
CAGR 3-Years
-2%
CAGR 5-Years
-9%
CAGR 10-Years
-6%
Abbvie Inc
NYSE:ABBV
Inventory
$5B
CAGR 3-Years
11%
CAGR 5-Years
8%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Inventory
$1.8B
CAGR 3-Years
6%
CAGR 5-Years
1%
CAGR 10-Years
-1%
Amgen Inc
NASDAQ:AMGN
Inventory
$6.2B
CAGR 3-Years
8%
CAGR 5-Years
10%
CAGR 10-Years
10%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Inventory
$1.7B
CAGR 3-Years
54%
CAGR 5-Years
43%
CAGR 10-Years
40%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Inventory
$2.5B
CAGR 3-Years
1%
CAGR 5-Years
5%
CAGR 10-Years
26%
No Stocks Found

Cyclo Therapeutics Inc
Glance View

Market Cap
20.7m USD
Industry
Biotechnology

Cyclo Therapeutics, Inc. engages in the development of cyclodextrin-based biopharmaceuticals for the treatment of disease. The company is headquartered in Gainesville Florida, Florida and currently employs 9 full-time employees. The company went IPO on 2004-02-27. The firm's lead drug candidate, Trappsol Cyclo (hydroxypropyl beta cyclodextrin) is for the treatment of Niemann-Pick Type C disease (NPC). NPC is a rare and fatal cholesterol metabolism disease that impacts the brain, lungs, liver, spleen, and other organs. The company is also focusing on the use of cyclodextrins in the treatment of Alzheimer's disease. The firm's product lines include Trappsol and Aquaplex. The company sells its chemical products directly to customers in the pharmaceutical, diagnostics, and industrial chemical industries, and to chemical supply distributors. The firm also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs.

CYTH Intrinsic Value
326.76 USD
Undervaluation 70%
Intrinsic Value
Price $99

See Also

What is Cyclo Therapeutics Inc's Inventory?
Inventory
236.1k USD

Based on the financial report for Sep 30, 2024, Cyclo Therapeutics Inc's Inventory amounts to 236.1k USD.

What is Cyclo Therapeutics Inc's Inventory growth rate?
Inventory CAGR 10Y
-6%

Over the last year, the Inventory growth was 13%. The average annual Inventory growth rates for Cyclo Therapeutics Inc have been -2% over the past three years , -9% over the past five years , and -6% over the past ten years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett